The effect of Modafinil on improving consciousness with COVID-19

The effect of Modafinil and placebo on improving consciousness in patients with COVID-19 with loss of consciousness

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170903036041N3

Enrollment

Registered

2021-05-23

Start date

2021-05-05

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus 2019. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Modafinil (100 mg Tablets) is administered orally or by gavage at the rate of 100 mg every 8 hours and in case of no complications or changes in hemodynamics, 100 m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirm patient with clinical feature, laboratory and chest CT scan Having mild decrease level of consiousness, drowsiness to deep coma

Exclusion criteria

Exclusion criteria: History of seizure Clinical feature accompanied after drug cosumption Drug side effects

Design outcomes

Primary

Measure	Time frame
Level of consiousnesa. Timepoint: On admission and after 3 days. Method of measurement: Glasgow Coma Scale.;Headache. Timepoint: On admission and after 3 days. Method of measurement: Interview with the patient.;Seizure. Timepoint: On admission and after 3 days. Method of measurement: Observation, examination and recording data.	—

Secondary

Measure	Time frame
Biochemical laboratory data. Timepoint: Before intervention and daily in duration of intervention. Method of measurement: Laboratory kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaziar Emamikhah

Iran University of Medical Sciences

maziar.emamikhah@yahoo.com+98 21 6653 9260

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 6, 2026